{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:05:24Z","timestamp":1793480724359,"version":"4.5.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41582-025-01126-2","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T17:10:23Z","timestamp":1754932223000},"page":"506-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advances in PET imaging of protein aggregates associated with neurodegenerative disease"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3934-5810","authenticated-orcid":false,"given":"Makoto","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-597X","authenticated-orcid":false,"given":"Hironobu","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"1126_CR1","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer, A. \u00dcber eine eigenartige Erkrankung der Hirnrinde [German]. Allg. Z. Psychiat. 64, 146\u2013148 (1907).","journal-title":"Allg. Z. Psychiat."},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s13311-020-00853-2","volume":"17","author":"S Kwon","year":"2020","unstructured":"Kwon, S., Iba, M., Kim, C. & Masliah, E. Immunotherapies for aging-related neurodegenerative diseases \u2014 emerging perspectives and new targets. Neurotherapeutics 17, 935\u2013954 (2020).","journal-title":"Neurotherapeutics"},{"key":"1126_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"4","author":"VL Villemagne","year":"2015","unstructured":"Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L. & Rowe, C. C. Tau imaging: early progress and future directions. Lancet Neurol. 4, 114\u2013124 (2015).","journal-title":"Lancet Neurol."},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"Wilson","year":"2023","unstructured":"Wilson et al. Hallmarks of neurodegenerative diseases. Cell 186, 693\u2013714 (2023).","journal-title":"Cell"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00401-011-0839-6","volume":"122","author":"KA Josephs","year":"2011","unstructured":"Josephs, K. A. et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 122, 137\u2013153 (2011).","journal-title":"Acta Neuropathol."},{"key":"1126_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong, Y. C. & Krainc, D. \u03b1-Synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Med. 23, 1\u201313 (2017).","journal-title":"Nat. Med."},{"key":"1126_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-3-030-51140-1_13","volume":"1231","author":"M Neumann","year":"2021","unstructured":"Neumann, M., Lee, E. B. & Mackenzie, I. R. Frontotemporal lobar degeneration TDP-43-immunoreactive pathological subtypes: clinical and mechanistic significance. Adv. Exp. Med. Biol. 1231, 201\u2013217 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1126_CR8","first-page":"1","volume":"159","author":"RS Harrison","year":"2007","unstructured":"Harrison, R. S., Sharpe, P. C., Singh, Y. & Fairlie, D. P. Amyloid peptides and proteins in review. Rev. Physiol. Biochem. Pharmacol. 159, 1\u201377 (2007).","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1474-4422(04)00853-1","volume":"3","author":"A Nordberg","year":"2004","unstructured":"Nordberg, A. PET imaging of amyloid in Alzheimer\u2019s disease. Lancet Neurol. 3, 519\u2013527 (2004).","journal-title":"Lancet Neurol."},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","volume":"30","author":"V Pike","year":"2009","unstructured":"Pike, V. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci. 30, 431\u2013440 (2009).","journal-title":"Trends Pharmacol. Sci."},{"key":"1126_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-023-06437-2","volume":"621","author":"SHW Scheres","year":"2023","unstructured":"Scheres, S. H. W., Ryskeldi-Falcon, B. & Goedert, M. Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature 621, 701\u2013710 (2023).","journal-title":"Nature"},{"key":"1126_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fnins.2019.00659","volume":"13","author":"X-Q Chen","year":"2019","unstructured":"Chen, X.-Q. & Mobley, W. C. Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric A\u03b2 and tau species. Front. Neurosci. 13, 659 (2019).","journal-title":"Front. Neurosci."},{"key":"1126_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10759","volume":"7","author":"D Sehlin","year":"2016","unstructured":"Sehlin, D. et al. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease. Nat. Commun. 7, 10759 (2016).","journal-title":"Nat. Commun."},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.1999.7085","volume":"158","author":"J Wang","year":"1999","unstructured":"Wang, J., Dickson, D. W., Trojanowski, J. Q. & Lee, V. M. The levels of soluble versus insoluble brain A\u03b2 distinguish Alzheimer\u2019s disease from normal and pathologic aging. Exp. Neurol. 158, 328\u2013337 (1999).","journal-title":"Exp. Neurol."},{"key":"1126_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnmol.2014.00042","volume":"7","author":"S Tenreiro","year":"2014","unstructured":"Tenreiro, S., Eckermann, K. & Outeiro, T. F. Protein phosphorylation in neurodegeneration: friend or foe? Front. Mol. Neurosci. 7, 42 (2014).","journal-title":"Front. Mol. Neurosci."},{"key":"1126_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","volume":"1118","author":"J Cummings","year":"2019","unstructured":"Cummings, J. The role of biomarkers in Alzheimer\u2019s disease drug development. Adv. Exp. Med. Biol. 1118, 29\u201361 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1126_CR17","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"1126_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr.","year":"2016","unstructured":"Jack, C. R. Jr. et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539\u2013547 (2016).","journal-title":"Neurology"},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1126_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1126_CR21","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1007\/s00259-020-05120-2","volume":"48","author":"M Boccardi","year":"2021","unstructured":"Boccardi, M. et al. The Strategic Biomarker Roadmap for the validation of Alzheimer\u2019s diagnostic biomarkers: methodological update. Eur. J. Nucl. Med. Mol. Imaging 48, 2070\u20132085 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","volume":"52","author":"K Chiotis","year":"2017","unstructured":"Chiotis, K. et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Neurobiol. Aging 52, 214\u2013227 (2017).","journal-title":"Neurobiol. Aging"},{"key":"1126_CR23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00259-020-05118-w","volume":"48","author":"EE Wolters","year":"2021","unstructured":"Wolters, E. E. et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase biomarker development framework. Eur. J. Nucl. Med. Mol. Imaging 48, 2097\u20132109 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk, W. E. et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Ann. Neurol. 55, 306\u2013319 (2004).","journal-title":"Ann. Neurol."},{"key":"1126_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/mp.2014.9","volume":"19","author":"PM Doraiswamy","year":"2014","unstructured":"Doraiswamy, P. M. et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol. Psychiatry 19, 1044\u201310451 (2014).","journal-title":"Mol. Psychiatry"},{"key":"1126_CR26","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shchebinin","year":"2022","unstructured":"Shchebinin, S. et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes. JAMA Neurol. 79, 1015\u20131024 (2022).","journal-title":"JAMA Neurol."},{"key":"1126_CR27","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton, H. G. et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur. J. Nucl. Med. Mol. Imaging 49, 3508\u20133528 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11, 1\u201315 (2015).","journal-title":"Alzheimers Dement."},{"key":"1126_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 11, 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"key":"1126_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis, C. et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 72, 287\u2013294 (2015).","journal-title":"JAMA Neurol."},{"key":"1126_CR31","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri, O. et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 11, 964\u2013974 (2015).","journal-title":"Alzheimers Dement."},{"key":"1126_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 15, 205\u2013216 (2019).","journal-title":"Alzheimers Dement."},{"key":"1126_CR33","first-page":"467","volume":"317","author":"H Yamaguchi","year":"1989","unstructured":"Yamaguchi, H. et al. Alzheimer type dementia: diffuse type of senile plaques demonstrated by beta protein immunostaining. Prog. Clin. Biol. Res. 317, 467\u2013474 (1989).","journal-title":"Prog. Clin. Biol. Res."},{"key":"1126_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s004010050664","volume":"94","author":"JG Sheng","year":"1997","unstructured":"Sheng, J. G., Mrak, R. E. & Griffin, W. S. Neuritic plaque evolution in Alzheimer\u2019s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol. 94, 1\u20135 (1997).","journal-title":"Acta Neuropathol."},{"key":"1126_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118463","volume":"10","author":"R Mathur","year":"2015","unstructured":"Mathur, R. et al. A reduced astrocyte response to \u03b2-amyloid plaques in the ageing brain associates with cognitive impairment. PLoS ONE 10, e0118463 (2015).","journal-title":"PLoS ONE"},{"key":"1126_CR36","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3233\/JAD-160365","volume":"53","author":"M Malek-Ahmadi","year":"2016","unstructured":"Malek-Ahmadi, M., Perez, S. E., Chen, K. & Mufson, E. J. Neuritic and diffuse plaque associations with memory in non-cognitively impaired elderly. J. Alzheimers Dis. 53, 1641\u20131652 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"1126_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ana.22628","volume":"71","author":"CR Jack Jr","year":"2012","unstructured":"Jack, C. R. Jr et al. An operational approach to National Institute on Aging\u2013Alzheimer\u2019s Association criteria for preclinical Alzheimer disease. Ann. Neurol. 71, 765\u2013775 (2012).","journal-title":"Ann. Neurol."},{"key":"1126_CR38","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia. A meta-analysis. JAMA 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"1126_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.23931","volume":"74","author":"RC Petersen","year":"2013","unstructured":"Petersen, R. C. et al. Mild cognitive impairment due to Alzheimer\u2019s disease in the community. Ann. Neurol. 74, 199\u2013208 (2013).","journal-title":"Ann. Neurol."},{"key":"1126_CR40","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317, 2305\u20132316 (2017).","journal-title":"JAMA"},{"key":"1126_CR41","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer, R. & Abdalla, N. Estimation of lifetime risks of Alzheimer\u2019s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 14, 981\u2013988 (2018).","journal-title":"Alzheimers Dement."},{"key":"1126_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228\u2013243 (2022).","journal-title":"JAMA Neurol."},{"key":"1126_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413\u2013446 (2020).","journal-title":"Lancet"},{"key":"1126_CR44","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes. JAMA 313, 1939\u20131949 (2015).","journal-title":"JAMA"},{"key":"1126_CR45","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.002","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson, K. A. et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. Alzheimers Dement. 9, e1\u2013e16 (2013).","journal-title":"Alzheimers Dement."},{"key":"1126_CR46","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286\u20131294 (2019).","journal-title":"JAMA"},{"key":"1126_CR47","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A de Wilde","year":"2018","unstructured":"de Wilde, A. et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 75, 1062\u20131070 (2018).","journal-title":"JAMA Neurol."},{"key":"1126_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jamaneurol.2023.0997","volume":"80","author":"D Altomare","year":"2023","unstructured":"Altomare, D. et al. Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial. JAMA Neurol. 80, 548\u2013557 (2023).","journal-title":"JAMA Neurol."},{"key":"1126_CR49","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/alz.12846","volume":"19","author":"IS van Maurik","year":"2022","unstructured":"van Maurik, I. S. et al. A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. Alzheimers Dement. 19, 2006\u20132013 (2022).","journal-title":"Alzheimers Dement."},{"key":"1126_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"1126_CR51","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1126_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2022","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1126_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat. Med. 27, 1187\u20131196 (2021).","journal-title":"Nat. Med."},{"key":"1126_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","volume":"613","author":"S Reardon","year":"2023","unstructured":"Reardon, S. FDA approves Alzheimer\u2019s drug lecanemab amid safety concerns. Nature 613, 227\u2013228 (2023).","journal-title":"Nature"},{"key":"1126_CR55","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1523\/JNEUROSCI.2990-05.2005","volume":"25","author":"WE Klunk","year":"2005","unstructured":"Klunk, W. E. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-\u03b2 in Alzheimer\u2019s disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598\u201310606 (2005).","journal-title":"J. Neurosci."},{"key":"1126_CR56","doi-asserted-by":"publisher","first-page":"10957","DOI":"10.1523\/JNEUROSCI.0673-07.2007","volume":"27","author":"J Maeda","year":"2007","unstructured":"Maeda, J. et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer\u2019s disease enabled by positron emission tomography. J. Neurosci. 27, 10957\u201310968 (2007).","journal-title":"J. Neurosci."},{"key":"1126_CR57","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0896-6273(95)90301-1","volume":"14","author":"TC Saido","year":"1995","unstructured":"Saido, T. C. et al. Dominant and differential deposition of distinct \u03b2-amyloid peptide species, A\u03b2N3(pE), in senile plaques. Neuron 14, 457\u2013466 (1995).","journal-title":"Neuron"},{"key":"1126_CR58","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi, T. et al. Age-dependent changes in brain, CSF, and plasma amyloid \u03b2 protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease. J. Neurosci. 21, 372\u2013381 (2001).","journal-title":"J. Neurosci."},{"key":"1126_CR59","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00401-014-1287-x","volume":"127","author":"TA Bayer","year":"2014","unstructured":"Bayer, T. A. & Wirths, O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer\u2019s disease. Acta Neuropathol. 127, 787\u2013801 (2014).","journal-title":"Acta Neuropathol."},{"key":"1126_CR60","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s40478-019-0837-9","volume":"7","author":"DR Thal","year":"2019","unstructured":"Thal, D. R., Walter, J., Saido, T. C. & F\u00e4ndrich, M. Different aspects of Alzheimer\u2019s disease-related amyloid \u03b2-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathol. Commun. 7, 178 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"1126_CR61","doi-asserted-by":"publisher","first-page":"825.e1","DOI":"10.1016\/j.neurobiolaging.2011.05.003","volume":"33","author":"F Bao","year":"2012","unstructured":"Bao, F. et al. Different \u03b2-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol. Aging 33, 825.e1\u2013825.e13 (2012).","journal-title":"Neurobiol. Aging"},{"key":"1126_CR62","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.112.113654","volume":"54","author":"BNM van Berckel","year":"2013","unstructured":"van Berckel, B. N. M. et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J. Nucl. Med. 54, 1570\u20131576 (2013).","journal-title":"J. Nucl. Med."},{"key":"1126_CR63","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2967\/jnumed.117.204271","volume":"59","author":"VJ Lowe","year":"2018","unstructured":"Lowe, V. J. et al. White matter reference region in PET studies of 11C-Pittsburgh compound B uptake: effects of age and amyloid-\u03b2 deposition. J. Nucl. Med. 59, 1583\u20131589 (2018).","journal-title":"J. Nucl. Med."},{"key":"1126_CR64","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2967\/jnumed.117.200006","volume":"59","author":"S Southekal","year":"2018","unstructured":"Southekal, S. et al. Flortaucipir F 18 quantitation using parametric estimation of reference signal intensity. J. Nucl. Med. 59, 944\u2013951 (2018).","journal-title":"J. Nucl. Med."},{"key":"1126_CR65","doi-asserted-by":"publisher","first-page":"10857","DOI":"10.1523\/JNEUROSCI.1738-05.2005","volume":"25","author":"N Okamura","year":"2005","unstructured":"Okamura, N. et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer\u2019s disease. J. Neurosci. 25, 10857\u201310862 (2005).","journal-title":"J. Neurosci."},{"key":"1126_CR66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien, D. T. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457\u2013468 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"1126_CR67","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JAD-130098","volume":"38","author":"DT Chien","year":"2014","unstructured":"Chien, D. T. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J. Alzheimers Dis. 38, 171\u2013184 (2014).","journal-title":"J. Alzheimers Dis."},{"key":"1126_CR68","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","volume":"79","author":"M Maruyama","year":"2013","unstructured":"Maruyama, M. et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094\u20131108 (2013).","journal-title":"Neuron"},{"key":"1126_CR69","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110\u2013119 (2016).","journal-title":"Ann. Neurol."},{"key":"1126_CR70","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.115.164848","volume":"57","author":"R Harada","year":"2016","unstructured":"Harada, R. et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J. Nucl. Med. 57, 208\u2013214 (2016).","journal-title":"J. Nucl. Med."},{"key":"1126_CR71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","volume":"9","author":"KP Ng","year":"2017","unstructured":"Ng, K. P. et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res. Ther. 9, 25 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"1126_CR72","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marqui\u00e9","year":"2015","unstructured":"Marqui\u00e9, M. et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787\u2013800 (2015).","journal-title":"Ann. Neurol."},{"key":"1126_CR73","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2967\/jnumed.117.201632","volume":"59","author":"R Ni","year":"2018","unstructured":"Ni, R. et al. Comparative in vitro and in vivo quantifications of pathologic tau deposits and their association with neurodegeneration in tauopathy mouse models. J. Nucl. Med. 59, 960\u2013966 (2018).","journal-title":"J. Nucl. Med."},{"key":"1126_CR74","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.nucmedbio.2015.08.006","volume":"42","author":"H Hashimoto","year":"2015","unstructured":"Hashimoto, H. et al. Identification of a major radiometabolite of [11C]PBB3. Nucl. Med. Biol. 42, 905\u2013910 (2015).","journal-title":"Nucl. Med. Biol."},{"key":"1126_CR75","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ana.24706","volume":"80","author":"MD Ikonomovic","year":"2016","unstructured":"Ikonomovic, M. D., Abrahamson, E. E., Price, J. C., Mathis, C. A. & Klunk, W. E. [F-18]AV-1451 positron emission tomography retention in choroid plexus: more than \u201coff-target\u201d binding. Ann. Neurol. 80, 307\u2013308 (2016).","journal-title":"Ann. Neurol."},{"key":"1126_CR76","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","volume":"7","author":"C Aguero","year":"2019","unstructured":"Aguero, C. et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol. Commun. 7, 37 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"1126_CR77","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2967\/jnumed.117.196741","volume":"59","author":"M Honer","year":"2018","unstructured":"Honer, M. et al. Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J. Nucl. Med. 59, 675\u2013681 (2018).","journal-title":"J. Nucl. Med."},{"key":"1126_CR78","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","volume":"46","author":"H Kroth","year":"2019","unstructured":"Kroth, H. et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies. Eur. J. Nucl. Med. Mol. Imaging 46, 2178\u20132189 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR79","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","volume":"46","author":"S Sanabria Boh\u00f3rquez","year":"2019","unstructured":"Sanabria Boh\u00f3rquez, S. et al. [18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease. Eur. J. Nucl. Med. Mol. Imaging 46, 2077\u20132089 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR80","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai, K. et al. High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies. Neuron 109, 42\u201358.e8 (2021).","journal-title":"Neuron"},{"key":"1126_CR81","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1177\/0271678X211031035","volume":"41","author":"SL Baker","year":"2021","unstructured":"Baker, S. L. et al. Evaluation of [18F]-JNJ-64326067-AAA tau PET tracer in humans. J. Cereb. Blood Flow. Metab. 41, 3302\u20133313 (2021).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"1126_CR82","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"M Goedert","year":"1989","unstructured":"Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D. & Crowther, R. A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease. Neuron 3, 519\u2013526 (1989).","journal-title":"Neuron"},{"key":"1126_CR83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 5\u201321 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"1126_CR84","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson, D. W., Kouri, N., Murray, M. E. & Josephs, K. A. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 45, 384\u2013389 (2011).","journal-title":"J. Mol. Neurosci."},{"key":"1126_CR85","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-022-02426-3","volume":"143","author":"A Tarutani","year":"2022","unstructured":"Tarutani, A. et al. Ultrastructural and biochemical classification of pathogenic tau, \u03b1-synuclein and TDP-43. Acta Neuropathol. 143, 613\u2013640 (2022).","journal-title":"Acta Neuropathol."},{"key":"1126_CR86","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy, A. et al. Tau PET imaging in neurodegenerative tauopathies \u2014 still a challenge. Mol. Psychiatry 24, 1112\u20131134 (2019).","journal-title":"Mol. Psychiatry"},{"key":"1126_CR87","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.24844","volume":"81","author":"M Marqui\u00e9","year":"2017","unstructured":"Marqui\u00e9, M. et al. Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann. Neurol. 81, 117\u2013128 (2017).","journal-title":"Ann. Neurol."},{"key":"1126_CR88","first-page":"764","volume":"140","author":"M Ono","year":"2017","unstructured":"Ono, M. et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 764\u2013780 (2017).","journal-title":"Brain"},{"key":"1126_CR89","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","volume":"28","author":"ML Malarte","year":"2023","unstructured":"Malarte, M. L. et al. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol. Psychiatry 28, 1272\u20131283 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1126_CR90","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel, M. et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 77, 1408\u20131419 (2020).","journal-title":"JAMA Neurol."},{"key":"1126_CR91","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/mds.27643","volume":"34","author":"H Endo","year":"2019","unstructured":"Endo, H. et al. In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy. Mov. Disord. 34, 744\u2013754 (2019).","journal-title":"Mov. Disord."},{"key":"1126_CR92","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.parkreldis.2022.04.015","volume":"98","author":"Y Nakano","year":"2022","unstructured":"Nakano, Y. et al. PET-based classification of corticobasal syndrome. Parkinsonism Relat. Disord. 98, 92\u201398 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1126_CR93","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.28672","volume":"36","author":"L Li","year":"2021","unstructured":"Li, L. et al. Clinical utility of 18F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy. Mov. Disord. 36, 2314\u20132323 (2021).","journal-title":"Mov. Disord."},{"key":"1126_CR94","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/mds.29173","volume":"37","author":"H Endo","year":"2022","unstructured":"Endo, H. et al. A machine learning-based approach to discrimination of tauopathies using [18F]PM-PBB3 PET images. Mov. Disord. 37, 2236\u20132246 (2022).","journal-title":"Mov. Disord."},{"key":"1126_CR95","doi-asserted-by":"publisher","first-page":"fcab190","DOI":"10.1093\/braincomms\/fcab190","volume":"3","author":"T Tezuka","year":"2021","unstructured":"Tezuka, T. et al. Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun. 3, fcab190 (2021).","journal-title":"Brain Commun."},{"key":"1126_CR96","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Structure-based classification of tauopathies. Nature 598, 359\u2013363 (2021).","journal-title":"Nature"},{"key":"1126_CR97","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00401-021-02294-3","volume":"141","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease with PET ligand APN-1607. Acta Neuropathol. 141, 697\u2013708 (2021).","journal-title":"Acta Neuropathol."},{"key":"1126_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/alz.066995","volume":"18","author":"ML Alosco","year":"2022","unstructured":"Alosco, M. L. et al. 18F-MK-6240 tau PET as a biomarker for chronic traumatic encephalopathy: case series of 10 symptomatic former National Football League players. Alzheimers Dement. 18, e066995 (2022).","journal-title":"Alzheimers Dement."},{"key":"1126_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38537-y","volume":"14","author":"GE Merz","year":"2023","unstructured":"Merz, G. E. et al. Stacked binding of a PET ligand to Alzheimer\u2019s tau paired helical filaments. Nat. Commun. 14, 3048 (2023).","journal-title":"Nat. Commun."},{"key":"1126_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52265-x","volume":"15","author":"P Kunach","year":"2023","unstructured":"Kunach, P. et al. Cryo-EM structure of Alzheimer\u2019s disease tau filaments with PET ligand MK-6240. Nat. Commun. 15, 8497 (2023).","journal-title":"Nat. Commun."},{"key":"1126_CR101","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00259-022-05963-x","volume":"50","author":"ML Alosco","year":"2023","unstructured":"Alosco, M. L. et al. Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players. Eur. J. Nucl. Med. Mol. Imaging 50, 435\u2013452 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/alz.041510","volume":"16","author":"K Takahata","year":"2020","unstructured":"Takahata, K. et al. Grouping tau topologies in former boxers assessed by PET with 18F-PM-PBB3: a reappraisal of dementia pugilistica. Alzheimers Dement. 16, e041510 (2020).","journal-title":"Alzheimers Dement."},{"key":"1126_CR103","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40478-023-01565-2","volume":"11","author":"C Qi","year":"2023","unstructured":"Qi, C. et al. Identical tau filaments in subacute sclerosing panencephalitis and chronic traumatic encephalopathy. Acta Neuropathol. Commun. 11, 74 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"1126_CR104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2306767120","volume":"120","author":"C Qi","year":"2023","unstructured":"Qi, C. et al. Tau filaments from amyotrophic lateral sclerosis\/parkinsonism-dementia complex adopt the CTE fold. Proc. Natl Acad. Sci. USA 120, e2306767120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1126_CR105","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H. & Del Tredici, K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389\u2013404 (2006).","journal-title":"Acta Neuropathol."},{"key":"1126_CR106","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak, H. & Braak, E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol. Aging 16, 271\u2013278 (1995).","journal-title":"Neurobiol. Aging"},{"key":"1126_CR107","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971\u2013982 (2016).","journal-title":"Neuron"},{"key":"1126_CR108","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818\u20132830 (2020).","journal-title":"Brain"},{"key":"1126_CR109","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955\u2013965 (2020).","journal-title":"JAMA Neurol."},{"key":"1126_CR110","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151\u20131162 (2018).","journal-title":"JAMA"},{"key":"1126_CR111","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/ph14020110","volume":"14","author":"CVML Jie","year":"2021","unstructured":"Jie, C. V. M. L., Treyer, V., Schibli, R. & Mu, L. Tauvid\u2122: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals 14, 110 (2021).","journal-title":"Pharmaceuticals"},{"key":"1126_CR112","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2023.1067","volume":"80","author":"A Leuzy","year":"2023","unstructured":"Leuzy, A. et al. Comparison of group-level and individualized brain regions for measuring change in longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 80, 614\u2013623 (2023).","journal-title":"JAMA Neurol."},{"key":"1126_CR113","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat. Med. 27, 871\u2013881 (2021).","journal-title":"Nat. Med."},{"key":"1126_CR114","volume":"15","author":"VL Villemagne","year":"2023","unstructured":"Villemagne, V. L. et al. CenTauR: toward a universal scale and masks for standardizing tau imaging studies. Alzheimers Dement. 15, e12454 (2023).","journal-title":"Alzheimers Dement."},{"key":"1126_CR115","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher, A. S. et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 77, 829\u2013839 (2020).","journal-title":"JAMA Neurol."},{"key":"1126_CR116","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","volume":"81","author":"C Groot","year":"2024","unstructured":"Groot, C. et al. Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairment. JAMA Neurol. 81, 845\u2013856 (2024).","journal-title":"JAMA Neurol."},{"key":"1126_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01602-5","volume":"11","author":"S-D Chen","year":"2021","unstructured":"Chen, S.-D. et al. Staging tau pathology with tau PET in Alzheimer\u2019s disease: a longitudinal study. Transl. Psychiatry 11, 483 (2021).","journal-title":"Transl. Psychiatry"},{"key":"1126_CR118","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755\u2013766 (2014).","journal-title":"Acta Neuropathol."},{"key":"1126_CR119","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/brain\/awad135","volume":"146","author":"A Wuestefeld","year":"2023","unstructured":"Wuestefeld, A. et al. Age-related and amyloid-beta-independent tau deposition and its downstream effects. Brain 146, 3192\u20133205 (2023).","journal-title":"Brain"},{"key":"1126_CR120","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2967\/jnumed.120.245423","volume":"62","author":"VL Villemagne","year":"2021","unstructured":"Villemagne, V. L. et al. What is T+? A Gordian Knot of tracers, thresholds, and topographies. J. Nucl. Med. 62, 614\u2013619 (2021).","journal-title":"J. Nucl. Med."},{"key":"1126_CR121","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961\u2013971 (2021).","journal-title":"JAMA Neurol."},{"key":"1126_CR122","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s00259-021-05246-x","volume":"48","author":"D Altomare","year":"2021","unstructured":"Altomare, D. et al. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. Eur. J. Nucl. Med. Mol. Imaging 48, 2200\u20132211 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR123","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1212\/WNL.0000000000201389","volume":"100","author":"S Shimohama","year":"2023","unstructured":"Shimohama, S. et al. Impact of amyloid and tau PET on changes in diagnosis and patient management. Neurology 100, e264\u2013e274 (2023).","journal-title":"Neurology"},{"key":"1126_CR124","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamaneurol.2023.1323","volume":"80","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. Clinical utility of tau positron emission tomography in the diagnostic workup of patients with cognitive symptoms. JAMA Neurol. 80, 749\u2013756 (2023).","journal-title":"JAMA Neurol."},{"key":"1126_CR125","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1126_CR126","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1126_CR127","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","volume":"79","author":"E Teng","year":"2022","unstructured":"Teng, E. et al. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 79, 758\u2013767 (2022).","journal-title":"JAMA Neurol."},{"key":"1126_CR128","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards, A. L. et al. Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 80, 1344\u20131352 (2023).","journal-title":"JAMA Neurol."},{"key":"1126_CR129","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat. Med. 29, 1437\u20131447 (2023).","journal-title":"Nat. Med."},{"key":"1126_CR130","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.14283\/jpad.2022.101","volume":"10","author":"N Ziogas","year":"2023","unstructured":"Ziogas, N. et al. Exploratory clinical outcomes from BIIB080 (MAPT ASO) phase 1b multiple ascending dose and long-term extension study in mild Alzheimer\u2019s disease. J. Prev. Alz. Dis. 10, S41 (2023).","journal-title":"J. Prev. Alz. Dis."},{"key":"1126_CR131","doi-asserted-by":"publisher","unstructured":"Endo, H. et al. Correlation of 18F-PM-PBB3 (18F-florzolotau) tau PET imaging with postmortem neuropathological findings in a case with progressive supranuclear palsy (P9-11.015) [abstract]. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000201875 (2023).","DOI":"10.1212\/WNL.0000000000201875"},{"key":"1126_CR132","doi-asserted-by":"publisher","first-page":"119763","DOI":"10.1016\/j.neuroimage.2022.119763","volume":"264","author":"K Tagai","year":"2022","unstructured":"Tagai, K. et al. An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with 18F-PM-PBB3 (18F-APN-1607). Neuroimage 264, 119763 (2022).","journal-title":"Neuroimage"},{"key":"1126_CR133","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1002\/alz.13908","volume":"20","author":"A Leuzy","year":"2024","unstructured":"Leuzy, A. et al. Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: the CenTauR scale and the joint propagation model. Alzheimers Dement. 20, 5833\u20135848 (2024).","journal-title":"Alzheimers Dement."},{"key":"1126_CR134","first-page":"301","volume":"11","author":"T van Eimeren","year":"2019","unstructured":"van Eimeren, T. et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a neuroimaging biomarker utility system. Alzheimers Dement. 11, 301\u2013309 (2019).","journal-title":"Alzheimers Dement."},{"key":"1126_CR135","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"1126_CR136","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1093\/brain\/awv114","volume":"138","author":"MD Cykowski","year":"2015","unstructured":"Cykowski, M. D. et al. Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 138, 2293\u20132309 (2015).","journal-title":"Brain"},{"key":"1126_CR137","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/brain\/awq091","volume":"133","author":"A Kikuchi","year":"2010","unstructured":"Kikuchi, A. et al. In vivo visualization of \u03b1-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 133, 1772\u20131778 (2010).","journal-title":"Brain"},{"key":"1126_CR138","doi-asserted-by":"publisher","first-page":"9165458","DOI":"10.1155\/2018\/9165458","volume":"2018","author":"M Verdurand","year":"2018","unstructured":"Verdurand, M. et al. Amyloid-beta radiotracer [18F]BF-227 does not bind to cytoplasmic glial inclusions of postmortem multiple system atrophy brain tissue. Contrast Media Mol. Imaging 2018, 9165458 (2018).","journal-title":"Contrast Media Mol. Imaging"},{"key":"1126_CR139","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mds.27013","volume":"32","author":"S Koga","year":"2017","unstructured":"Koga, S., Ono, M., Sahara, N., Higuchi, M. & Dickson, D. W. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to \u03b1-synuclein pathology. Mov. Disord. 32, 884\u2013892 (2017).","journal-title":"Mov. Disord."},{"key":"1126_CR140","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/mds.29159","volume":"37","author":"FT Liu","year":"2022","unstructured":"Liu, F. T. et al. 18F-florzolotau tau positron emission tomography imaging in patients with multiple system atrophy-parkinsonian subtype. Mov. Disord. 37, 1915\u20131923 (2022).","journal-title":"Mov. Disord."},{"key":"1126_CR141","doi-asserted-by":"publisher","first-page":"108985","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin, S. et al. In vivo imaging of \u03b1-synuclein with antibody-based PET. Neuropharmacology 208, 108985 (2022).","journal-title":"Neuropharmacology"},{"key":"1126_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202303921","volume":"30","author":"JY Pees","year":"2024","unstructured":"Pees, J. Y. et al. Development of pyridothiophene compounds for PET imaging of \u03b1-synuclein aggregates. Chem. Eur. J. 30, e202303921 (2024).","journal-title":"Chem. Eur. J."},{"key":"1126_CR143","doi-asserted-by":"publisher","first-page":"12185","DOI":"10.1021\/acs.jmedchem.3c00779","volume":"66","author":"HY Kim","year":"2023","unstructured":"Kim, H. Y. et al. A novel brain PET radiotracer for imaging alpha synuclein fibrils in multiple system atrophy. J. Med. Chem. 66, 12185\u201312202 (2023).","journal-title":"J. Med. Chem."},{"key":"1126_CR144","doi-asserted-by":"publisher","first-page":"12345","DOI":"10.1021\/acs.jmedchem.4c00686","volume":"67","author":"Q Zeng","year":"2024","unstructured":"Zeng, Q. et al. Discovery and evaluation of imidazo[2,1-b][1,3,4]thiadiazole derivatives as new candidates for \u03b1-synuclein PET imaging. J. Med. Chem. 67, 12345\u201312358 (2024).","journal-title":"J. Med. Chem."},{"key":"1126_CR145","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/app4010066","volume":"4","author":"X Zhang","year":"2014","unstructured":"Zhang, X. et al. Radiosynthesis and in vivo evaluation of two PET radioligands for imaging \u03b1-synuclein. Appl. Sci. 4, 66\u201378 (2014).","journal-title":"Appl. Sci."},{"key":"1126_CR146","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","volume":"48","author":"L Kuebler","year":"2021","unstructured":"Kuebler, L. et al. [11C]MODAG-001 \u2014 towards a PET tracer targeting \u03b1-synuclein aggregates. Eur. J. Nucl. Med. Mol. Imaging 48, 1759\u20131772 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1126_CR147","doi-asserted-by":"publisher","first-page":"830704","DOI":"10.3389\/fnagi.2022.830704","volume":"14","author":"\u0160 Korat","year":"2022","unstructured":"Korat, \u0160. et al. Toward novel [18F]fluorine-labeled radiotracers for the imaging of \u03b1-synuclein fibrils. Front. Aging Neurosci. 14, 830704 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1126_CR148","doi-asserted-by":"publisher","first-page":"24774","DOI":"10.1021\/acsomega.4c01301","volume":"9","author":"F Bonanno","year":"2024","unstructured":"Bonanno, F. et al. Advancing Parkinson\u2019s disease diagnostics: the potential of arylpyrazolethiazole derivatives for imaging \u03b1-synuclein aggregates. ACS Omega 9, 24774\u201324788 (2024).","journal-title":"ACS Omega"},{"key":"1126_CR149","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/cmdc.201900689","volume":"15","author":"A Maurer","year":"2020","unstructured":"Maurer, A. et al. 11C radiolabeling of anle253b: a putative PET tracer for Parkinson\u2019s disease that binds to \u03b1-synuclein fibrils in vitro and crosses the blood-brain barrier. ChemMedChem 15, 411\u2013415 (2020).","journal-title":"ChemMedChem"},{"key":"1126_CR150","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s11307-023-01814-9","volume":"25","author":"B Janssen","year":"2023","unstructured":"Janssen, B. et al. Identification of a putative \u03b1-synuclein radioligand using an in silico similarity search. Mol. Imaging Biol. 25, 704\u2013719 (2023).","journal-title":"Mol. Imaging Biol."},{"key":"1126_CR151","doi-asserted-by":"publisher","first-page":"24339","DOI":"10.1021\/acsomega.3c04292","volume":"8","author":"A Di Nanni","year":"2023","unstructured":"Di Nanni, A. et al. A fluorescent probe as a lead compound for a selective \u03b1-synuclein PET tracer. ACS Omega 8, 24339\u201324352 (2023).","journal-title":"ACS Omega"},{"key":"1126_CR152","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1039\/D4OB00492B","volume":"22","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. Development of an \u00b9\u2078F-labeled azobenzothiazole tracer for \u03b1-synuclein aggregates in the brain. Org. Biomol. Chem. 22, 3724\u20133732 (2024).","journal-title":"Org. Biomol. Chem."},{"key":"1126_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32797-w","volume":"13","author":"L Antonschmidt","year":"2022","unstructured":"Antonschmidt, L. et al. The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils. Nat. Commun. 13, 5285 (2022).","journal-title":"Nat. Commun."},{"key":"1126_CR154","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1021\/acschemneuro.8b00177","volume":"9","author":"CJ Hsieh","year":"2018","unstructured":"Hsieh, C. J. et al. Alpha synuclein fibrils contain multiple binding sites for small molecules. ACS Chem. Neurosci. 9, 2521\u20132527 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"1126_CR155","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo, H. et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112, 2540\u20132557.e8 (2024).","journal-title":"Neuron"},{"key":"1126_CR156","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190 (2017).","journal-title":"Nature"},{"key":"1126_CR157","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. \u03b1-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1126_CR158","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s40478-021-01291-7","volume":"9","author":"JA Macdonald","year":"2021","unstructured":"Macdonald, J. A. et al. Assembly of \u03b1-synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of \u03b1-synuclein seeds. Acta Neuropathol. Commun. 9, 189 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1126_CR159","doi-asserted-by":"publisher","first-page":"147131","DOI":"10.1016\/j.brainres.2020.147131","volume":"1749","author":"P Miranda-Azpiazu","year":"2020","unstructured":"Miranda-Azpiazu, P. et al. Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res. 1749, 147131 (2020).","journal-title":"Brain Res."},{"key":"1126_CR160","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/mds.29186","volume":"37","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka, K. et al. High-contrast imaging of \u03b1-synuclein pathologies in living patients with multiple system atrophy. Mov. Disord. 37, 2159\u20132161 (2022).","journal-title":"Mov. Disord."},{"key":"1126_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 2023).","journal-title":"Nat. Commun."},{"key":"1126_CR162","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell 186, 3350\u20133367.e19 (2023).","journal-title":"Cell"},{"key":"1126_CR163","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-021-04199-3","volume":"601","author":"D Arseni","year":"2022","unstructured":"Arseni, D. et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601, 139\u2013143 (2022).","journal-title":"Nature"},{"key":"1126_CR164","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11307-022-01779-1","volume":"25","author":"AC Knight","year":"2023","unstructured":"Knight, A. C. et al. Head-to-head comparison of tau-PET radioligands for imaging TDP-43 in post-mortem ALS brain. Mol. Imaging Biol. 25, 513\u2013527 (2023).","journal-title":"Mol. Imaging Biol."},{"key":"1126_CR165","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41586-023-06405-w","volume":"620","author":"D Arseni","year":"2023","unstructured":"Arseni, D. et al. TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP. Nature 620, 898\u2013903 (2023).","journal-title":"Nature"},{"key":"1126_CR166","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-024-08024-5","volume":"634","author":"D Arseni","year":"2024","unstructured":"Arseni, D. et al. Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP type C. Nature 634, 662\u2013668 (2024).","journal-title":"Nature"},{"key":"1126_CR167","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-013-1089-6","volume":"125","author":"EH Bigio","year":"2013","unstructured":"Bigio, E. H. et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 125, 463\u2013465 (2013).","journal-title":"Acta Neuropathol."},{"key":"1126_CR168","doi-asserted-by":"publisher","DOI":"10.1002\/alz.075525","volume":"19","author":"T Seredenina","year":"2023","unstructured":"Seredenina, T. et al. Discovery and optimization of the first-in-class TDP-43 PET tracer. Alzheimers Dement. 19, e075525 (2023).","journal-title":"Alzheimers Dement."},{"key":"1126_CR169","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina, S. et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain 144, 2186\u20132198 (2021).","journal-title":"Brain"},{"key":"1126_CR170","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41586-022-04650-z","volume":"605","author":"M Schweighauser","year":"2022","unstructured":"Schweighauser, M. et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature 605, 310\u2013314 (2022).","journal-title":"Nature"},{"key":"1126_CR171","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41586-022-04670-9","volume":"605","author":"YX Jiang","year":"2022","unstructured":"Jiang, Y. X. et al. Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Nature 605, 304\u2013309 (2022).","journal-title":"Nature"},{"key":"1126_CR172","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00401-022-02531-3","volume":"145","author":"J Perneel","year":"2023","unstructured":"Perneel, J. et al. Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging. Acta Neuropathol. 145, 285\u2013302 (2023).","journal-title":"Acta Neuropathol."},{"key":"1126_CR173","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel, H. et al. Blood-based biomarkers for Alzheimer\u2019s disease: mapping the road to the clinic. Nat. Rev. Neurol. 14, 639\u2013652 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1126_CR174","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1126_CR175","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"1126_CR176","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40035-024-00439-4","volume":"13","author":"K Tagai","year":"2023","unstructured":"Tagai, K. et al. A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer\u2019s disease. Transl. Neurodegener. 13, 44 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1126_CR177","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","volume":"31","author":"K Horie","year":"2025","unstructured":"Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease. Nat. Med. 31, 2044\u20132053 (2025).","journal-title":"Nat. Med."},{"key":"1126_CR178","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp-2022-330619","volume":"94","author":"D Altomare","year":"2023","unstructured":"Altomare, D. et al. Plasma biomarkers for Alzheimer\u2019s disease: a field-test in a memory clinic. J. Neurol. Neurosurg. Psychiatry 94, 420\u2013427 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1126_CR179","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46603-2","volume":"15","author":"WS Brum","year":"2024","unstructured":"Brum, W. S. et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat. Commun. 15, 2311 (2024).","journal-title":"Nat. Commun."},{"key":"1126_CR180","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3233\/JPD-130247","volume":"3","author":"JL Eberling","year":"2013","unstructured":"Eberling, J. L., Dave, K. D. & Frasier, M. A. \u03b1-Synuclein imaging: a critical need for Parkinson\u2019s disease research. J. Parkinsons Dis. 3, 565\u2013567 (2013).","journal-title":"J. Parkinsons Dis."},{"key":"1126_CR181","first-page":"285","volume":"20","author":"T Suhara","year":"2017","unstructured":"Suhara, T. et al. Strategies for utilizing neuroimaging biomarkers in CNS drug discovery and development: CINP\/JSNP working group report. Int. J. Neuropsychopharmacol. 20, 285\u2013294 (2017).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1126_CR182","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal, D. R. et al. Neuropathology and biochemistry of A\u03b2 and its aggregates in Alzheimer\u2019s disease. Acta Neuropathol. 129, 167\u2013182 (2015).","journal-title":"Acta Neuropathol."},{"key":"1126_CR183","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","volume":"97","author":"M Sch\u00f6ll","year":"2019","unstructured":"Sch\u00f6ll, M. et al. Biomarkers for tau pathology. Mol. Cell Neurosci. 97, 18\u201333 (2019).","journal-title":"Mol. Cell Neurosci."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01126-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01126-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01126-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:21:46Z","timestamp":1757377306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01126-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":183,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01126-2","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"15 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H. holds patents on PBB3, florzolotau and related compounds (JP 5422782\/EP 12 884 742.3\/CA2894994\/HK1208672) and \u03b1-synuclein ligands (JP7460176). M.H. is supported by research grants from the Japan Agency for Medical Research and Development (JP24zf0127012 and JP24wm0625001) and Japan Science and Technology Agency (JPMJMS2024). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}